B cell focused transient immune suppression protocol for efficient AAV readministration to the liver.

"Declaration of interests R.W.H. serves on the scientific advisory boards and committees of Regeneron Pharmaceuticals, Pfizer, Biomarin, Spark Therapeutics, Hoffman-La Roche, and Prevail Therapeutics. D.D. serves on the scientific advisory boards of Solid Biosciences and Sardocor Corporation. M.B. serves on the steering committee of Pfizer."

"This work was supported by 10.13039/100000002NIH grants R01HL131093, to C.T. and R.W.H.; by P01HL160472, to R.W.H.; by R01 AI51390, Indiana Collaborative Initiative for Talent Enrichment funds (provided by Lilly Endowment), and the 10.13039/100016606Riley Children's Foundation, to R.W.H.; and by R01 AI177600, to D.D. and R.W.H., and R21 HL170146 to M.B. The authors thank the members of the Indiana University Melvin and Bren Simon Cancer Center Flow Cytometry Resource Facility for their outstanding technical support. The Indiana University Melvin and Bren Simon Comprehensive Cancer Center Flow Cytometry Resource Facility (FCRF) is funded in part by NIH, 10.13039/100000054National Cancer Institute grant P30CA082709, and 10.13039/100000062National Institute of Diabetes and Digestive and Kidney Diseases grant U54DK106846 (Cooperative Center of Excellence in Hematology). The FCRF is further supported in part by 10.13039/100000002NIH instrumentation grant 1S10D012270."